Payment overview · 2025
General Payments
$8,493.56
167 reported records · 40 companies
Healthcare provider profile · identity verified
Behzad Molavi, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Interventional Cardiology · BRIGHTON, CO · NPI 1306936885
Verified facts
What the public records show
CMS Open Payments records show Behzad Molavi, M.D. received $8,493.56 in general payments during 2025 across 167 reported records.
AngioDynamics, Inc. accounted for 25.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 57 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Farxiga by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 235 claims for Eliquis by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Entresto by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 235 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AngioDynamics, Inc. | Unresolved — no canonical attribution shown | $2,139.40 | 25.2% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$1,849.32 | 21.8% | 27 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $619.11 | 7.3% | 6 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $459.52 | 5.4% | 15 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $313.71 | 3.7% | 14 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $313.17 | 3.7% | 12 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $262.13 | 3.1% | 9 | 2025 |
| W. L. Gore & Associates, Inc. | Unresolved — no canonical attribution shown | $240.41 | 2.8% | 3 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $236.06 | 2.8% | 7 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $187.85 | 2.2% | 9 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $171.29 | 2.0% | 7 | 2025 |
| HEARTFLOW, INC. | Unresolved — no canonical attribution shown | $170.25 | 2.0% | 10 | 2025 |
| Shockwave Medical, Inc | Unresolved — no canonical attribution shown | $167.71 | 2.0% | 1 | 2025 |
| Penumbra, Inc. | Unresolved — no canonical attribution shown | $150.72 | 1.8% | 1 | 2025 |
| BIOTRONIK INC. | Unresolved — no canonical attribution shown | $130.13 | 1.5% | 1 | 2025 |
| CVRx, Inc. | Unresolved — no canonical attribution shown | $119.20 | 1.4% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $116.23 | 1.4% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $115.78 | 1.4% | 4 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $69.43 | 0.8% | 3 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $66.01 | 0.8% | 2 | 2025 |
| United Therapeutics Corporation | Unresolved — no canonical attribution shown | $60.61 | 0.7% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $57.23 | 0.7% | 3 | 2025 |
| Bard Peripheral Vascular, Inc. | Unresolved — no canonical attribution shown | $53.58 | 0.6% | 3 | 2025 |
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $51.98 | 0.6% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $41.94 | 0.5% | 2 | 2025 |
| Kaneka Medical America LLC | Unresolved — no canonical attribution shown | $41.35 | 0.5% | 1 | 2025 |
| Ionis Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $34.32 | 0.4% | 1 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $32.85 | 0.4% | 1 | 2025 |
| CARDIVA MEDICAL, INC. | Unresolved — no canonical attribution shown | $31.62 | 0.4% | 1 | 2025 |
| BridgeBio Pharma, Inc. | Unresolved — no canonical attribution shown | $27.62 | 0.3% | 1 | 2025 |
| Reflow Medical Inc | Unresolved — no canonical attribution shown | $20.16 | 0.2% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $20.09 | 0.2% | 1 | 2025 |
| Teleflex LLC | Unresolved — no canonical attribution shown | $19.98 | 0.2% | 1 | 2025 |
| Becton, Dickinson and Company | Unresolved — no canonical attribution shown | $18.28 | 0.2% | 1 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $16.90 | 0.2% | 1 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $16.61 | 0.2% | 1 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $15.93 | 0.2% | 1 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $14.34 | 0.2% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $13.81 | 0.2% | 1 | 2025 |
| Reprise Biomedical, Inc. | Unresolved — no canonical attribution shown | $6.93 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $5,802.69 | 161 |
| Long term medical supply or device loan | $1,958.33 | 1 |
| Travel and Lodging | $643.54 | 4 |
| Education | $89.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Auryon Laser System 100-120 Vac Normalized: auryon laser system 100 120 vac |
Device | AngioDynamics, Inc. | $1,958.33 | 1 | 2025 |
Source payment records
|
|||||
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $1,434.87 | 17 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $313.71 | 14 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $271.04 | 10 | 2025 |
Source payment records
|
|||||
| ESPRIT Normalized: esprit |
Device | Abbott Laboratories | $270.69 | 2 | 2025 |
Source payment records
|
|||||
| Varithena Administration Pack Normalized: varithena administration pack |
Device | Boston Scientific Corporation | $267.82 | 11 | 2025 |
Source payment records
|
|||||
| AMVUTTRA Normalized: amvuttra |
Drug | Alnylam Pharmaceuticals Inc. | $262.13 | 9 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $236.06 | 7 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $236.06 | 7 | 2025 |
Source payment records
|
|||||
| GORE CARDIOFORM Septal Occluder Normalized: gore cardioform septal occluder |
Device | W. L. Gore & Associates, Inc. | $226.14 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $187.85 | 9 | 2025 |
Source payment records
|
|||||
| ANGIOVAC Normalized: angiovac |
Device | AngioDynamics, Inc. | $181.07 | 1 | 2025 |
Source payment records
|
|||||
| COREVALVE EVOLUT R Normalized: corevalve evolut r |
Device | Medtronic, Inc. | $178.96 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $171.29 | 7 | 2025 |
Source payment records
|
|||||
| FFRct Normalized: ffrct |
Device | HEARTFLOW, INC. | $170.25 | 10 | 2025 |
Source payment records
|
|||||
| Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Normalized: shockwave ivl system with the shockwave c2 coronary ivl catheter |
Device | Shockwave Medical, Inc | $167.71 | 1 | 2025 |
Source payment records
|
|||||
| RUBY Coil Normalized: ruby coil |
Device | Penumbra, Inc. | $150.72 | 1 | 2025 |
Source payment records
|
|||||
| PERCLOSE PROGLIDE Normalized: perclose proglide |
Device | Abbott Laboratories | $145.66 | 1 | 2025 |
Source payment records
|
|||||
| General - Balloon Catheters Normalized: general balloon catheters |
Device | Boston Scientific Corporation | $145.61 | 2 | 2025 |
Source payment records
|
|||||
| PROCLAIM Normalized: proclaim |
Device | Abbott Laboratories | $141.04 | 1 | 2025 |
Source payment records
|
|||||
| BIOMONITOR Normalized: biomonitor |
Device | BIOTRONIK INC. | $130.13 | 1 | 2025 |
Source payment records
|
|||||
| Barostim Neo System Normalized: barostim neo system |
Device | CVRx, Inc. | $119.20 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $116.23 | 5 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $115.78 | 4 | 2025 |
Source payment records
|
|||||
| MICRA Normalized: micra |
Device | Medtronic, Inc. | $114.71 | 2 | 2025 |
Source payment records
|
|||||
| VENASEAL Normalized: venaseal |
Device | Medtronic, Inc. | $75.48 | 3 | 2025 |
Source payment records
|
|||||
| EVKEEZA Normalized: evkeeza |
Biological | Regeneron Healthcare Solutions, Inc. | $66.01 | 2 | 2025 |
Source payment records
|
|||||
| Tyvaso Normalized: tyvaso |
Drug | United Therapeutics Corporation | $60.61 | 2 | 2025 |
Source payment records
|
|||||
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $51.98 | 2 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $51.98 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $41.94 | 2 | 2025 |
Source payment records
|
|||||
| Apheresis Machine Normalized: apheresis machine |
Device | Kaneka Medical America LLC | $41.35 | 1 | 2025 |
Source payment records
|
|||||
| JETI PERIPHERAL CATHETER Normalized: jeti peripheral catheter |
Device | Abbott Laboratories | $39.31 | 1 | 2025 |
Source payment records
|
|||||
| WAINUA Normalized: wainua |
Drug | AstraZeneca Pharmaceuticals LP | $35.53 | 2 | 2025 |
Source payment records
|
|||||
| TRYNGOLZA Normalized: tryngolza |
Drug | Ionis Pharmaceuticals, Inc. | $34.32 | 1 | 2025 |
Source payment records
|
|||||
| CLOSUREFAST Normalized: closurefast |
Device | Medtronic, Inc. | $33.65 | 2 | 2025 |
Source payment records
|
|||||
| Labosys Normalized: labosys |
Device | Philips North America LLC | $32.85 | 1 | 2025 |
Source payment records
|
|||||
| CARDIVA VASCADE MVP VVCS 6-12F Normalized: cardiva vascade mvp vvcs 6 12f |
Device | CARDIVA MEDICAL, INC. | $31.62 | 1 | 2025 |
Source payment records
|
|||||
| Attruby Normalized: attruby |
Drug | BridgeBio Pharma, Inc. | $27.62 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $23.81 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $23.31 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN Normalized: watchman |
Device | Boston Scientific Corporation | $22.78 | 1 | 2025 |
Source payment records
|
|||||
| DIAMONDBACK PERIPHERAL Normalized: diamondback peripheral |
Device | Abbott Laboratories | $22.41 | 1 | 2025 |
Source payment records
|
|||||
| LifeStream Normalized: lifestream |
Device | Bard Peripheral Vascular, Inc. | $20.42 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $20.09 | 1 | 2025 |
Source payment records
|
|||||
| TRAPLINER Normalized: trapliner |
Device | Teleflex LLC | $19.98 | 1 | 2025 |
Source payment records
|
|||||
| Adempas Normalized: adempas |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $19.62 | 1 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $16.90 | 1 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $16.61 | 1 | 2025 |
Source payment records
|
|||||
| RotarexS 6 F x 135 cm Normalized: rotarexs 6 f x 135 cm |
Device | Bard Peripheral Vascular, Inc. | $16.61 | 1 | 2025 |
Source payment records
|
|||||
| PleurX Normalized: pleurx |
Device | Bard Peripheral Vascular, Inc. | $16.55 | 1 | 2025 |
Source payment records
|
|||||
| REVCORE THROMBECTOMY CATHETER Normalized: revcore thrombectomy catheter |
Device | Stryker Corporation | $15.93 | 1 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $14.34 | 1 | 2025 |
Source payment records
|
|||||
| GORE VIABAHN VBX Balloon Expandable Endo Normalized: gore viabahn vbx balloon expandable endo |
Device | W. L. Gore & Associates, Inc. | $14.27 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $13.81 | 1 | 2025 |
Source payment records
|
|||||
| ONYX FRONTIER Normalized: onyx frontier |
Device | Medtronic, Inc. | $11.65 | 1 | 2025 |
Source payment records
|
|||||
| Miro3D Normalized: miro3d |
Device | Reprise Biomedical, Inc. | $6.93 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 235 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
40 | 17 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
52 | 12 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
235 | 53 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
235 | 53 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Eliquis | Apixaban | 235 | 53 |
| Clopidogrel | Clopidogrel Bisulfate | 186 | 63 |
| Atorvastatin Calcium | Atorvastatin Calcium | 167 | 50 |
| Carvedilol | Carvedilol | 116 | 38 |
| Metoprolol Tartrate | Metoprolol Tartrate | 115 | 40 |
| Metoprolol Succinate | Metoprolol Succinate | 106 | 33 |
| Losartan Potassium | Losartan Potassium | 97 | 29 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 80 | 28 |
| Lisinopril | Lisinopril | 75 | 24 |
| Amlodipine Besylate | Amlodipine Besylate | 74 | 29 |
| Furosemide | Furosemide | 56 | 22 |
| Chlorthalidone | Chlorthalidone | 52 | 13 |
| Farxiga | Dapagliflozin Propanediol | 52 | 12 |
| Xarelto | Rivaroxaban | 42 | 12 |
| Brilinta | Ticagrelor | 40 | 17 |
| Potassium Chloride | Potassium Chloride | 37 | 14 |
| Amiodarone Hcl | Amiodarone Hcl | 36 | suppressed |
| Simvastatin | Simvastatin | 36 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 34 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 25 | suppressed |
| Nitroglycerin | Nitroglycerin | 23 | 12 |
| Ranolazine Er | Ranolazine | 23 | suppressed |
| Repatha Sureclick | Evolocumab | 20 | suppressed |
| Entresto | Sacubitril/Valsartan | 18 | suppressed |
| Repatha Syringe | Evolocumab | 18 | suppressed |
| Spironolactone | Spironolactone | 17 | suppressed |
| Metolazone | Metolazone | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Ezetimibe | Ezetimibe | 13 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 12 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 11 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 11 | suppressed |
| Multaq | Dronedarone Hcl | 11 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $8,493.56 · 167 records | AngioDynamics, Inc. | AMVUTTRA, ANGIOVAC, Adempas, Apheresis Machine, Attruby, Auryon Laser System 100-120 Vac, BIOMONITOR, Barostim Neo System, CAMZYOS, CARDIVA VASCADE MVP VVCS 6-12F, CLOSUREFAST, COREVALVE EVOLUT R, DIAMONDBACK PERIPHERAL, ELIQUIS, ESPRIT, EVKEEZA, FFRct, FUROSCIX, Flexitouch Plus, GORE CARDIOFORM Septal Occluder, GORE VIABAHN VBX Balloon Expandable Endo, General - Balloon Catheters, INJECTAFER, JARDIANCE, JETI PERIPHERAL CATHETER, Kerendia, LEQVIO, Labosys, LifeStream, LifeVest, MICRA, Miro3D, NEXLETOL, Nimbl, ONYX FRONTIER, OPSUMIT, PERCLOSE PROGLIDE, PROCLAIM, PleurX, REPATHA, REVCORE THROMBECTOMY CATHETER, RUBY Coil, RotarexS 6 F x 135 cm, SYMPLICITY G3, Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter, TRAPLINER, TRYNGOLZA, Tyvaso, UPTRAVI, VENASEAL, VYNDAQEL, Varithena Administration Pack, WAINUA, WATCHMAN, WATCHMAN Access System, Wegovy, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error